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Each year, an estimated 2 to 4 million human
Salmonella infections occur in the United States
(1,2). Although most of these infections cause a
mild, self-limiting illness, serious sequelae,
including invasive infections and death can occur
(1,2). Antimicrobial therapy is not recommended
for routine treatment of salmonellosis; however,
appropriate antimicrobial therapy can be life-
saving for patients with invasive disease. Since
antimicrobial agents are essential for treating
some Salmonella infections, isolates from such
infections should be monitored for antimicrobial
resistance, particularly resistance to fluoroquino-
lones (e.g., ciprofloxacin). Fluoroquinolones have
been in human clinical use in the United States
since the mid-1980s and are recommended for
treating invasive Salmonella infections in adults
(3,4). Resistance to nalidixic acid—the prototypic
quinolone—has been found in some instances to
precede resistance to fluoroquinolones (5).
To determine the prevalence of antimicrobial
resistance among Salmonella isolates in the
United States, we conducted a study between
July 1, 1994, and June 30, 1995. All state public
health laboratories sent every tenth nontyphoidal
Salmonella isolate they received to the Centers
for Disease Control and Prevention for anti-
microbial testing. Isolates were tested by the disk
diffusion method for resistance to 12 antimicrobial
agents, including two quinolones, nalidixic acid,
and ciprofloxacin. For ciprofloxacin-resistant iso-
lates, the minimum inhibitory concentration for
ciprofloxacin was also determined.
Antimicrobial resistance patterns were
determined for 4,008 Salmonella isolates
received from 51 states and territories. Emerging
quinolone resistance was detected; 21 isolates
(0.5%) were resistant to nalidixic acid, and one
(0.02%) was resistant to ciprofloxacin. The 21
nalidixic acid-resistant strains included 13 diff-
erent serotypes from 15 states. The most com-
mon serotypes were Typhimurium (5 isolates),
Enteriditis (3), and Virchow (2).
The ciprofloxacin-resistant strain, Salmo-
nella  serotype Schwarzengrund, was isolated in
January 1995 from the stool of a woman referred
to a hospital in the United States for treatment of
complications caused by factor VIII deficiency.
She had been hospitalized in the Philippines in
September 1994 for “amoebic colitis,” which was
treated with antimicrobial agents; the patient
could not recall the names of the agents. At that
time, she also received a blood transfusion for
severe anemia. Examination in the U.S. hospital
showed a factor VIII level of 5% with a factor VIII
inhibitor titer of 20 Bethesda units. The patient
was afebrile and did not have diarrhea or other
gastrointestinal symptoms, however, blood was
observed in her stool on the second day of
hospitalization. Colonoscopy showed angio-
dysplasia of the right colon. She was not treated
with antimicrobial agents and was discharged
from the hospital after 15 days.
To our knowledge, this is only the second
reported isolation of fluoroquinolone-resistant
Salmonella in the United States; the first
reported isolate was from a patient who had been
treated with three courses of ciprofloxacin for 8
weeks (6). The resistant pathogen found in our
study was probably acquired in the Philippines,
where quinolones have been available without
prescription at least since 1987 (7) and where,
according to a 1992 survey, 2.5% of non-
typhoidal  Salmonella  isolates were resistant to
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fluoroquinolones (5). Fluoroquinolone-resistant
Salmonella have also been reported in Asia and
Europe (5,8,9). Prior hospitalization, prior anti-
microbial treatment (6), and travel outside the
United States have been shown to increase the
risk of being infected with Salmonella resistant
to antimicrobial agents (10).
Compared with the previous national study,
conducted in 1989-1990, which found one in 758
(0.1%) Salmonella isolates resistant to nalidixic
acid, we found a fivefold increase in the pre-
valence of nalidixic acid resistance. Although
increasing, the low prevalence of quinolone
resistance in Salmonella in the United States
and the lack of domestically acquired fluoro-
quinolone-resistant strains, is in sharp contrast
to the situation in England and Wales, where
increasing prevalence has been reported (8),
particularly among isolates of S. Typhimurium,
S. Virchow, and S. Hadar (E.J. Threlfall, L.R.
Ward, J.A. Skinner, B. Rowe, unpub. obs.).
Among one particular Salmonella strain, Sal-
monella Typhimurium Definitive Type 104 (DT
104), which was the second most frequently
isolated  Salmonella  strain from humans in the
United Kingdom in 1995, the incidence of
fluoroquinolone resistance has increased from
0% in 1993 to 6% in 1995 (11), and has more than
doubled in 1996 (Public Health Laboratory
System, unpub. data). An important factor
contributing to this increase may be the licensing
in 1993 of the fluoroquinolone antimicrobial
enrofloxacin for general veterinary use in that
country (11). Although the only fluoroquinolone-
resistant  Salmonella isolate identified in our
study was apparently acquired outside, DT 104
has emerged widely in the United States (12).
The recent approval of a fluoroquinolone for use
in animals intended for food in the United States
(sarafloxacine in poultry) (13) may contribute to
the emergence and circulation of fluoroquinolone-
resistant strains in a way analogous to that
already observed in the United Kingdom. Since
fluoroquinolones are important in treating
invasive  Salmonella infections and most DT 104
isolates are already resistant to ampicillin,
chlorampenicol, streptomycin, sulphonamides,
and tetracyclines, continued monitoring of
salmonellas for resistance to fluoroquinolone
antimicrobial drugs is warranted.
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